Drug intelligence / Profile preview

FL-501

Development stage
Discontinued
Lead developer
Leap Therapeutics
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Parenteral
01

Overview

FL-501 is a fully human, monoclonal antibody engineered to neutralize growth differentiation factor 15 (GDF-15), a cytokine implicated in cancer cachexia and a range of GDF-15-related diseases. It prevents GDF-15 from binding its receptor, resulting in reversal of immunosuppression in certain cancers and improvement of weight loss and muscle mass. FL-501 features enhanced target affinity and an extended plasma half-life compared to prior antibodies. Preclinical models demonstrate full restoration of body composition in cachexia, superior pharmacokinetics, and potential efficacy in immune stimulation and organ protection. Developed and currently being advanced by Leap Therapeutics, initially originated by Flame Biosciences and Adimab, FL-501 is planned for clinical trials in cachexia and other GDF-15-linked conditions including certain cancers[1][2][3][4][5][6][7][9].

Other names
FL-501FL501FL 501
02

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on FL-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL-501.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call